Michael Mason - 01 Jun 2021 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role: EVP, CFO, Treasurer
Signature: /s/ Nancy Smith as Attorney-in-Fact for Michael Mason
Issuer symbol: KPTI
Transactions as of: 01 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 01 Jun 2021, 17:53:29 UTC
Next filing: 09 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPTI	Common Stock	Award	$0	+5,500	+11%	$0.000000	57,255	01 Jun 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KPTI	Stock Option (right to buy)	Award	$0	+15,000		$0.000000	15,000	01 Jun 2021	Common Stock	15,000	$9.15	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning June 1, 2022.
F2	This option was granted on June 1, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on June 1, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.